GSP 301 NS

Phase 3Small molecule

GGlenmark Specialty S.A.

GSP 301 NS is one of 60 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 3

Rayos

RRoxane Laboratories

Phase 3

1 4

Kenalog

BBassett Healthcare

Phase 3

1 5

Active Comparator

Moderna

Phase 3

1 6

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 7

Flonase

Teva

Phase 3

1 8

Allegra-D

Pfizer

Phase 3

3 9

Asmanex

Novartis

Preclinical

12 10

GSP 301 NS

GGlenmark Specialty S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis3 trials

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Completed·GGlenmark Specialty S.A.·Phase 3·NCT02631551·1,180 enrolled

Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)

Completed·GGlenmark Specialty S.A.·Phase 3·NCT03463031·446 enrolled

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

Completed·GGlenmark Specialty S.A.·Phase 3·NCT02870205·1,176 enrolled

Allergic Rhinitis1 trial

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

Completed·GGlenmark Specialty S.A.·Phase 3·NCT02709538·601 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for GSP 301 NS. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSP 301 NS compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSP 301 NS. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Glenmark Specialty S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGlenmark Specialty S.A.

GSP 301 NS

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seasonal Allergic Rhinitis3 trials

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News